At Prosemble,
we are redefining cancer treatment…
Through groundbreaking innovation in nanotechnology and AI-driven drug delivery. As a spin-out from King’s College London, with a world-class team of scientists, AI specialists, and industry leaders, we are committed to pioneering breakthrough treatments that bring hope to millions.
Company History
Prosemble’s journey began as a remarkable story of resilience, change chance encounters to serendipity, and groundbreaking science.
It all started when Dr. Julien Bergeron, then a postdoctoral researcher at the University of Washington School of Medicine in Seattle, working in the lab of Professor Justin Kollman, first encountered a previously unknown bacterial protein. Although the team recognised its potential for use in targeted drug delivery, they were unable to determine its structure at the time. Years later, at King’s College London, Dr. Bergeron revisited the protein—named BeeR—applying advanced imaging techniques. With the support of a talented team including Dr. Alexandra Parker, Shamar Lale-Farjat, Hanna Lewicka, and Chloe Parry, he discovered that in the presence of ATP, BeeR assembled into three strands forming a hollow tubular structure. Though its biological function remained elusive, the discovery of an actin-like protein forming such a structure offered a transformative insight into the evolution of this important protein family.
Despite the scientific breakthrough, the team lacked the commercial experience needed to bring the innovation to market. Then, a series of extraordinary and seemingly fated events unfolded. In 2022, Ukrainian scientist Iryna Peretiazhko arrived in the UK through the Ukraine Sponsorship Scheme, fleeing the war with little more than hope and in need of both housing and employment. At the same time, Inna Zhuranskaya—a senior leader in private equity with a deep background in biotech investment and former leadership roles at Alkor Bio Group and Astra Biotech GmbH—was assisting refugee resettlement efforts. Inna, who had worked alongside leading figures such as Sir Christopher Evans OBE and the late Professor Sir Ian Wilmut, as well as with the Universities of Newcastle, UCL, and Edinburgh, happened to meet Iryna because of these efforts. Iryna soon found a role in Dr. Bergeron’s laboratory and, recognising Inna’s superb commercialisation abilities, introduced her to him.
That fortuitous introduction led to the founding of Prosemble, a spin-out from King’s College London. Bringing together scientific ingenuity and commercial expertise, Prosemble quickly positioned itself at the forefront of medical innovation. Today, the company pioneers the use of AI and nanotechnology to transform drug delivery and redefine the future of cancer treatment.
Mission & Vision
At Prosemble, our mission is to revolutionise cancer treatment by integrating advanced nanoparticle technology and artificial intelligence, ensuring more effective therapies with fewer side effects.
We believe in a future where precision medicine is not just an ambition but a reality, where every patient receives the right treatment at the right time, maximising efficacy while minimising harm.
Our vision is to lead the next generation of targeted drug delivery, creating breakthrough solutions that improve patient outcomes and set new standards in oncology care.
Through Our Science We Are Transforming Cancer Treatment for Chemotherapy Patients
